Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects of a single dose have not been investigated.
Aims:
To investigate the pharmacokinetics, feasibility, safety and efficacy of single-dose psilocybin therapy in AUD.
Methods:
This open-label, single-group study investigated single-dose psilocybin therapy in 10 treatment-seeking adults (8 men and 2 women; median age 44 years) with severe AUD. The treatment involved two preparation sessions, a high-dose psilocybin session (25 mg) and two integration sessions. Pharmacokinetics were determined by noncompartmental analysis, and changes in alcohol consumption, craving and self-efficacy, were assessed using a linear mixed model.
Results:
Notable between-participant pharmacokinetic variations were observed, with peak plasma psilocin concentrations ranging from 14 to 59 µg/L. Alcohol consumption significantly decreased over the 12 weeks following psilocybin administration. Heavy drinking days were reduced by 37.5 percentage points (95% CI: −61.1 to −13.9, p = 0.005), and drinks per day decreased by 3.4 drinks (95% CI: −6.5 to −0.3, p = 0.03). This was corroborated by reports of rapid and sustained reductions in craving and increases in self-efficacy.
Conclusions:
Despite pharmacokinetic variations, a single 25 mg psilocybin dose was safe and effective in reducing alcohol consumption in AUD patients. Larger randomised, placebo-controlled, single-dose AUD trials are warranted.
BeckerAMHolzeFGrandinettiT, et al. (2022) Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Therap111: 886–895.
2.
BogenschutzMPRossSBhattS, et al. (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy versus placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry79: 953–962.
3.
BogenschutzMPForcehimesAAPommyJA, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol29: 289–299.
4.
BondFWHayesSCBaerRA, et al. (2011) Preliminary psychometric properties of the Acceptance and Action Questionnaire–II: A revised measure of psychological inflexibility and experiential avoidance. Behav Ther42: 676–688.
5.
BonnyHLPahnkeWN (1972) The use of music in psychedelic (LSD) psychotherapy. J Music Ther9: 64–87.
6.
BrownKWRyanRM (2003) The benefits of being present: Mindfulness and its role in psychological well-being. J Personal Soc Psychol84: 822.
7.
BrownRTNicholasCRCozziNV, et al. (2017) Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet56: 1543–1554.
8.
BuckeridgeCDuvvuriSDenneyWS (2015) Simple, automatic noncompartmental analysis: The PKNCA R package.J Pharmacokinet Pharmacodyn42: 11–107.
9.
ChwelosNBlewettDBSmithCM, et al. (1959) Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quart J Stud Alcohol20: 577–590.
10.
DavisAKBarrettFSGriffithsRR (2020) Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Context Behav Sci15: 39–45.
11.
DiClementeCCCarbonariJPMontgomeryRP, et al. (1994) The alcohol abstinence self-efficacy scale. J Stud Alcohol55: 141–148.
12.
Dinis-OliveiraRJ (2017) Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance. Drug Metab Rev49: 84–91.
13.
DossMKPovažanMRosenbergMD, et al. (2021) Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry11: 1–10.
14.
FlanaganTWNicholsCD (2018) Psychedelics as anti-inflammatory agents. Int Rev Psychiatry30: 363–375.
15.
FlanneryBAVolpicelliJRPettinatiHM (1999) Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res23: 1289–1295.
16.
Garcia-RomeuABarrettFSCarbonaroTM, et al. (2021) Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. J Psychopharmacol35: 353–361.
17.
GoodwinGMAaronsonSTAlvarezO, et al. (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med387: 1637–1648.
18.
GoodwinGMMalievskaiaEFonzoGA, et al. (2024) Must psilocybin always “assist psychotherapy.”Am J Psychiatry181: 20–25.
19.
GriffithsRRJohnsonMWCarducciMA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol30: 1181–1197.
20.
GriffithsRRRichardsWAMcCannU, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl)187: 268–283.
21.
HaijenECHMKaelenMRosemanL, et al. (2018) Predicting responses to psychedelics: A prospective study. Front Pharmacol9: 897.
22.
HaslerFBourquinDBrenneisenR, et al. (1997) Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv72: 175–184.
23.
HayesSCLuomaJBBondFW, et al. (2006) Acceptance and commitment therapy: Model, processes and outcomes. Behav Res Ther44: 1–25.
24.
HeinzerlingKGSergiKLintonM, et al. (2023) Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder. Front Psychiatry14: 1215972.
25.
HeuschkelKKuypersKPC (2020) Depression, mindfulness, and psilocybin: Possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review. Front Psychiatry11: 224.
26.
HolzeFBeckerAMKolaczynskaKE, et al. (2023) Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. Clin Pharmacol Ther113: 822–831.
27.
HolzeFLeyLMüllerF, et al. (2022) Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology47: 1180–1187.
28.
HolzeFSinghNLiechtiME, et al. (2024) Serotonergic psychedelics–A comparative review comparing the efficacy, safety, pharmacokinetics and binding profile of serotonergic psychedelics. Biol Psychiatry Cogn Neurosci Neuroimaging9: 472–489.
29.
HovmandOREbbesen JensenMSøgaard JuulT, et al. (2024a) Validation of the Danish Translation of the Revised Mystical Experience Questionnaire (MEQ30) and possible impact of setting, dose and intention. J Psychoact Drugs1–10. DOI: 10.1080/02791072.2024.2302186.
30.
HovmandORMadsenMKFisherPM, et al. (2024b) Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire. J Psychopharmacol38: 924–932.
31.
JensenMEStenbækDSJuulTS, et al. (2022) Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: Protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). BMJ Open12: e066019.
32.
JohnsonMRichardsWGriffithsR (2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol22: 603–620.
33.
JohnsonMWGarcia-RomeuACosimanoMP, et al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol28: 983–992.
34.
KaminskiDReinertJP (2023) The tolerability and safety of psilocybin in psychiatric and substance-dependence conditions: A systematic review. Ann Pharmacother58: 811–826.
35.
KoKKnightGRuckerJJ, et al. (2022) Psychedelics, mystical experience, and therapeutic efficacy: A systematic review. Front Psychiatry13: 917199.
36.
KrebsTSJohansenPØ (2012) Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol26: 994–1002.
37.
LakensD (2013) Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Front Psychol4: 863.
38.
LeyLHolzeFArikciD, et al. (2023) Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology48: 1659–1667.
39.
LundgrenTLuomaJBDahlJ, et al. (2012) The bull’s-eye values survey: A psychometric evaluation. Cogn Behav Pract19: 518–526.
40.
LyCGrebACCameronLP, et al. (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep23: 3170–3182.
41.
MadsenMKFisherPMBurmesterD, et al. (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology44: 1328–1334.
42.
MadsenMKFisherPMStenbækDS, et al. (2020) A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur Neuropsychopharmacol33: 71–80.
43.
MeinhardtMWPfarrSFouquetG, et al. (2021) Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. Sci Adv7: eabh2399.
44.
MessellCDSummerLBondeLO, et al. (2022) Music programming for psilocybin-assisted therapy: Guided imagery and music-informed perspectives. Front Psychol13: 873455.
45.
MillerWRRollnickS (2012) Motivational Interviewing: Helping People Change. New York, NY: Guilford Press.
NourMMEvansLNuttD, et al. (2016) Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Front Hum Neurosci10: 269.
48.
NuttDErritzoeDCarhart-HarrisR (2020) Psychedelic psychiatry’s brave new world. Cell181: 24–28.
49.
OlsenLRJensenDVNoerholmV, et al. (2003) The internal and external validity of the Major Depression Inventory in measuring severity of depressive states. Psychol Med33: 351–356.
50.
OzenneBFormanJ (2024) LMMstar: Repeated measurement models for discrete times. R package version 1.1.0.
51.
PagniBAPetridisPDPodrebaracSK, et al. (2024) Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: An fMRI pilot study. Sci Rep14: 3159.
52.
PahnkeWN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin5: 149–162.
53.
RaisonCL, et al. (2023) Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA330: 843–853.
54.
RitzCBatyFStreibigJC, et al. (2015) Dose-response analysis using R. PLoS One10: e0146021.
55.
RosemanLHaijenEIdialu-IkatoK, et al. (2019) Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. J Psychopharmacol33: 1076–1087.
56.
RosemanLNuttDJCarhart-HarrisRL (2018) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol8: 974.
57.
RossSBossisAGussJ, et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol30: 1165–1180.
58.
SaundersJBAaslandOGBaborTF, et al. (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction88: 791–804.
59.
SloshowerJZeifmanRJGussJ, et al. (2024) Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: Results from an exploratory placebo-controlled trial. Sci Rep14: 8833.
60.
SobellLCSobellMB (1992) Measuring Alcohol Consumption Timeline Follow-Back. Totowa, NJ: Humana Press, pp. 41–72.
61.
SøndergaardAMadsenMKOzenneB, et al. (2022) Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. Front Psychol13: 948729.
62.
SpriggsMJGiribaldiBLyonsT, et al. (2023) Body mass index (BMI) does not predict responses to psilocybin. J Psychopharmacol37: 107–116.
63.
StenbækDSMadsenMKOzenneB, et al. (2021) Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J Psychopharmacol35: 459–468.
64.
TeamRS (2020) RStudio: Integrated Development for R. Boston, MA: RStudio, PBC.
65.
van ElkMYadenDB (2022) Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. Neurosci Biobehav Rev140: 104793.
66.
von RotzRSchindowskiEMJungwirthJ, et al. (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine56: 101809.
67.
WeathermonRCrabbDW (1999) Alcohol and medication interactions. Alcohol Res Health23: 40.
68.
WickhamHChangWWickhamMH (2016) Package “ggplot2.” Create elegant data visualisations using the grammar of graphics. Version, 2, pp. 1–189.
69.
YadenDBGriffithsRR (2020) The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Trans Sci4: 568–572.
70.
ZafarRSiegelMHardingR, et al. (2023) Psychedelic therapy in the treatment of addiction: The past, present and future. Front Psychiatry14: 1183740.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
